TY - JOUR
T1 - A review on 1,1-bis(diphenylphosphino)methane bridged homo- and heterobimetallic complexes for anticancer applications
T2 - Synthesis, structure, and cytotoxicity
AU - Odachowski, Matylda
AU - Marschner, Christoph
AU - Blom, Burgert
N1 - Funding Information:
The authors would like to thank Maastricht University and The Faculty of Science and Engineering for support.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/10/15
Y1 - 2020/10/15
N2 - Herein, we review developments in synthesis, structure, and biological (anti-cancer) activities of 1,1-bis(diphenylphosphino)methane (dppm) bridged homo- and heterobimetallic systems of the type LmM(μ2-dppm)M’Ln (M and M′ are transition metals which may be different or the same and Ln,m are co-ligands) since the first such reported bimetallic system in 1987 until the present time (2020). As the simplest diphosphine, dppm enables facile formation of bimetallic complexes, where, given the short spacer between the PPh2 groups, close spatial proximity of the metal centres is ensured. We concentrate on complexes bearing no M–M interaction and contrast biological activities of these complexes with mononuclear counterparts and positive control agents such as cisplatin, in an attempt to elucidate patterns in the biological activities of these complexes.
AB - Herein, we review developments in synthesis, structure, and biological (anti-cancer) activities of 1,1-bis(diphenylphosphino)methane (dppm) bridged homo- and heterobimetallic systems of the type LmM(μ2-dppm)M’Ln (M and M′ are transition metals which may be different or the same and Ln,m are co-ligands) since the first such reported bimetallic system in 1987 until the present time (2020). As the simplest diphosphine, dppm enables facile formation of bimetallic complexes, where, given the short spacer between the PPh2 groups, close spatial proximity of the metal centres is ensured. We concentrate on complexes bearing no M–M interaction and contrast biological activities of these complexes with mononuclear counterparts and positive control agents such as cisplatin, in an attempt to elucidate patterns in the biological activities of these complexes.
KW - Bimetallic complexes
KW - Heterobimetallic complexes
KW - Homobimetallic complexes
KW - Anti-cancer activity
KW - SILVER(I) 5,5-DIETHYLBARBITURATE COMPLEXES
KW - THIOREDOXIN REDUCTASE INHIBITION
KW - RAY CRYSTAL-STRUCTURE
KW - IN-VITRO
KW - ORGANOMETALLIC COMPOUNDS
KW - ANTITUMOR-ACTIVITY
KW - DNA-BINDING
KW - 2-ACETYLPYRIDINE THIOSEMICARBAZONES
KW - RUTHENIUM(II)-ARENE COMPOUND
KW - CYCLOPENTADIENYL COMPLEXES
U2 - 10.1016/j.ejmech.2020.112613
DO - 10.1016/j.ejmech.2020.112613
M3 - (Systematic) Review article
C2 - 32784095
SN - 0223-5234
VL - 204
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 112613
ER -